Aviex Technologies LLC was founded
to develop a novel vaccine platform delivery technology for infectious diseases.

Features and Benefits
of the new platform delivery technology:

About Us

Aviex Technologies LLC (Aviex) is an infectious disease vaccine development company using the enhanced Salmonella YS1646 vector. The company has initially undertaken the development of four high value vaccines relating to diseases that take a high toll in human suffering, often causing disability or death.

The three primary pathogens in which Aviex has demonstrated its platform delivery technology are Clostridiodes difficile, a bacterial disease of the gut initially limited to hospitals and now spreading throughout the general population. There are no licensed prophylactic vaccines to prevent C. difficile. The second is a prophylactic parasitic vaccine for Schistosoma mansoni and the third a therapeutic parasitic vaccine also for Schistosoma mansoni; an important global neglected tropical disease potentially affecting 800 million people on three continents. The fourth is a prophylactic vaccine for Cryptosporidium parvum, a disease affecting both human and animal health, which has a high mortality rate.

Brian J. Ward, M.D., MSc, MDCM, FRCP(C) is the Principal Investigator and also Chief Medical and Scientific Officer of Aviex. He is a Professor of Medicine and Microbiology; past-Chief, Division of Infectious Diseases at McGill University; Deputy Director, Fundamental Science at the Research Institute-McGill University Health Centre (RI-MUHC); Director of Vaccine Research at RI-MUHC; and Medical Director of the National Reference Center for Parasitology (NRCP).